Abstract: relevantie kan sterker in introductie This manuscript describes the study protocol of a relevant systematic review. It is clearly written.
This manuscript describes the study protocol of a relevant systematic review. It is clearly written. I have some minor comments. -The introduction could be considerably be shorter. Much of the information on the first page is so well-known, this could be described more concise. Yet, more attention could be paid to the role of the pharmacist why is it so important. There is information in the introduction but I miss a clear statement of what the positive impact of the pharmacist can be. Moreover, will GPs always accept pharmacy-led interventions it is part of your analysis, the acceptability but it could also be included more explicitly in the introduction). The manuscript would gain from more attention to theories/models on professional collaboration in primary care: what are models of cooperation, do they work etc. It could give some more depth to the study protocol. -My main point is the difference between pharmacist-led interventions (where pharmacists are the interventionists) and those in which pharmacists participated as target and are intervenees. I think these two types should be distinghuised as the role of the pharmacists in both types I so different. At least it should e addressed more explicitly in the analyses and it should receive more attention. But my preference would be to make a distinction as they are too different to include them as one group of studies. -I find the in-and exclusion criteria too complicated. They now are sometimes repetitive/redundant. For example , I would say: inclusion: intervention where the GP is the primary target or one of the primary targets instead . These statements could then be skipped from the exclusion criteria: o Intervention is received by any professional other than GPs in primary care o Intervention targets only patients as recipients o
Intervention is delivered to nurses, physicians other than general practitioner or dentists.
Why should studies have to include information on feasibility and acceptability? I can see it is important but it not necessarily needed to answer the primary research question. I would consider to skip this requirement. -I find the outcomes rather broad, for example the primary outcome: Change in total antibiotics (any type) prescribed by GPs or FPs. But total antibiotics can be defined in so many ways DDD, number of prescription. I would at least state, what types of outcomes you will include. Also the first part of the study outcome measures at page is very unclear and could e skipped (so just starting with effectiveness) -Why are key journals manually assessed? Shouldn't these come up in the search strategy? And how was determined what the key journals are. Is it impact combined with topic? -I recommend to use AMR instead of AR following the WHO) -A response limit of two weeks for manuscript authors of oncluded studies is rather short, especially when mails will be sent during holiday seasons.
VERSION 1 -AUTHOR RESPONSE

Responses:
Editorial Requirements:
1.
Please include an ethics and dissemination section in the main text of the manuscript. We have included ethics and dissemination section in the main text.
2. Please revise the Strengths and Limitations section (after the abstract) to focus on the methodological strengths and limitations of your study rather than summarizing the potential impact of the results.
We have deleted impact of results and revised methodological strengths and limitations
First Reviewer
No question Second reviewer 1. The introduction could be considerably be shorter. Much of the information on the first page is so well-known, this could be described more concise. Yet, more attention could be paid to the role of the pharmacist why is it so important. There is information in the introduction but I miss a clear statement of what the positive impact of the pharmacist can be. Moreover, will GPs always accept pharmacy-led interventions it is part of your analysis, the acceptability but it could also be included more explicitly in the introduction). The manuscript would gain from more attention to theories/models on professional collaboration in primary care: what are models of cooperation, do they work etc. It could give some more depth to the study protocol.
We thank the reviewer for these very helpful comments. We agree with second reviewer's noticeable points and background has been modified accordingly. Information on the first page has been made concise and role of pharmacists in changing clinicians/GPs antibiotic prescribing practice has been explained broadly with clear statement and evidences. What are existing models of collaboration between this two professional with their evidence of effectiveness and acceptability has been stated.
2. My main point is the difference between pharmacist-led interventions (where pharmacists are the interventionists) and those in which pharmacists participated as target and are intervenes. I think these two types should be distinguished as the role of the pharmacists in both types I so different. At least it should e addressed more explicitly in the analyses and it should receive more attention. But my preference would be to make a distinction as they are too different to include them as one group of studies.
Yes. We agree with your potential observation on the distinctive difference between two types of studies where pharmacists' role is completely different. However, this review will include only intervention studies where pharmacists are involved as interventionists not intervenes and GPs/FPs are intervenes or target of intervention.
3. I find the in-and exclusion criteria too complicated. They now are sometimes repetitive/redundant. For example , I would say: inclusion: intervention where the GP is the primary target or one of the primary targets instead . These statements could then be skipped from the exclusion criteria: o Intervention is received by any professional other than GPs in primary care o Intervention targets only patients as recipients o Intervention is delivered to nurses, physicians other than general practitioner or dentists.
Thanks reviewer for this point. In this review GP is the primary target of intervention. We tried to explicitly state the exclusion criteria although these have similar meaning with an inclusion criteria. We agree to skip these three points as these are of similar meaning and will have no impact on criteria of study selection for this review.
4. Why should studies have to include information on feasibility and acceptability? I can see it is important but it not necessarily needed to answer the primary research question. I would consider to skip this requirement.
We have considered feasibility and acceptability information as secondary outcomes in this review. The information on feasibility and acceptability not necessarily should be evaluated in the studies for inclusion in this review. We can drop this point from the list of inclusion criteria. It is to be highlighted in tone of the reviewer that these information are not required to answer the review question but equally very important for plausibility of intervention and their clinical importance in the future implementation and translation into real world.
5. I find the outcomes rather broad, for example the primary outcome: Change in total antibiotics (any type) prescribed by GPs or FPs. But total antibiotics can be defined in so many ways DDD, number of prescription. I would at least state, what types of outcomes you will include. Also the first part of the study outcome measures at page is very unclear and could be skipped (so just starting with effectiveness)
We thank the reviewer for this comment. We agree that total antibiotic prescription can be defined in many ways DDD, number of patient visit/consultation with antibiotics, proportion of prescription, per practitioner antibiotic prescription etc. The measurement unit of changes in prescribing has been presented as flexible as a number or percent or proportion of prescribed antibiotics in the section of effectiveness outcome as it is difficult to predict how data will be reported across studies. However, to make it clear, we have included the definition of the rate of antibiotic prescribing and rate of antibiotic prescribing adherence with guidelines to make outcome measures clear. First part of outcome measures has been skipped. This section has been started with effectiveness subheading.
6. Why are key journals manually assessed? Shouldn't these come up in the search strategy? And how was determined what the key journals are. Is it impact combined with topic?
We planned hand searching to some key journals to locate relevant items poorly indexed o r not indexed in databases and to ensure that relevant studies are not overlooked. Relevance with publishing similar study and high impact factor were considered to choose journals. Another reason was for checking the reference lists of particular journal articles, a process called snowballing.
I recommend to use AMR instead of AR following the WHO)
We focused on the prescribing of antibiotics not antimicrobials therefore we were strict to use AR. We will not consider intervention studies that deals with antiviral or antifungal or antiprotozoal or any antimicrobial prescription.
8. A response limit of two weeks for manuscript authors of included studies is rather short, especially when mails will be sent during holiday seasons.
We agree that two weeks are very short. However, we will avoid sending emails during holiday seasons. 
VERSION 2 -REVIEW REVIEWER
